Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vigabatrin - sanofi-aventis

X
Drug Profile

Vigabatrin - sanofi-aventis

Alternative Names: Gamma-vinyl-GABA; GVG; M071754; MDL 71754; RMI 71754; Sabril; Sabrilex; γ-vinyl-GABA

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi-aventis
  • Developer Alfresa Pharma Corporation; Lundbeck Inc; National Institute on Drug Abuse; Sanofi; sanofi-aventis
  • Class Aminobutyric acids; Antiepileptic drugs; Drug withdrawal therapies; Small molecules
  • Mechanism of Action 4-aminobutyrate transaminase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Infantile spasms; Epilepsy
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Complex partial epilepsy; Epilepsy; Infantile spasms
  • Discontinued Cocaine-related disorders; Substance-related disorders

Most Recent Events

  • 27 Jan 2020 The US FDA approves label expansion for vigabatrin for adjunctive treatment of Complex partial epilepsy in children 2 to 10 years of age in USA
  • 08 Aug 2019 Launched for Infantile spasms in Japan, prior August 2019 (PO)
  • 23 Jun 2016 The US FDA approves the modified Risk Evaluation and Mitigation Strategy (REMS) for vigabatrin
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top